APSR2026-489

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP11-035
P77
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1220701-46904-APSR26_Poster Template_AP11-035_432234.pdf
Format: PDF Only
09. Asthma
4

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Hongxia Lin * West China Hospital, Sichuan University Department of Respiratory and Critical Care Medicine Chengdu China
Yidan Qiao - West China Hospital, Sichuan University Department of Respiratory and Critical Care Medicine Chengdu China
Ji Wang - West China Hospital, Sichuan University Department of Respiratory and Critical Care Medicine Chengdu China
Gang Wang - West China Hospital, Sichuan University Department of Respiratory and Critical Care Medicine Chengdu China
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Hongxia
Lin
lhx01c61@rjh.com.cn
+8619121707389
31-40
China
Original Research
Efficacy of biologic treatments for mild-moderate asthma: A systematic review and meta‐analysis
Maximum 25 words
Abstract Content
The efficacy of biologics currently approved for mild-moderate asthma is unclear.This systematic review and meta‐analysis aims to evaluate the efficacy of biological therapies for mild-moderate asthma to assess the generalizability of the randomized controlled trials (RCT) data.
MEDLINE, Embase and CENTRAL were searched to identify RCT until 4 October 2025. We applied DerSimonian and Laird (DL) random-effects meta-analysis models for efficacy, including allergen-induced early asthmatic response (EAR), allergen-induced late asthmatic response (LAR) and markers of Type-2 (T2)-high inflammation (sputum eosinophils, fractional exhaled nitric oxide [FENO] and blood eosinophils).
We identified 11 studies, mostly including anti-TSLP antibodies, anti-IL13 antibodies and anti- IgE antibodies. In improving EAR compared with placebo: anti-TSLP antibodies (0.118, 95% CI: 0.041-0.194), anti-IgE antibodies (0.080, 95% CI: 0.024- 0.136). In improving LAR, anti-TSLP antibodies (0.092, 95% CI: 0.020-0.164), anti-IgE antibodies (0.166, 95% CI: 0.078- 0.253). In improving EAR change from baseline, anti-TSLP antibodies (0.091, 95% CI: 0.019- 0.164) and anti-IL13 antibodies (0.038, 95% CI: 0.018, 0.057). In improving LAR change from baseline, anti-TSLP antibodies (0.123, 95% CI: 0.052- 0.194) and anti-IL13 antibodies (0.090, 95% CI: 0.059, 0.122). Anti-TSLP antibodies induced sputum eosinophils, 7h-post allergen challenge (-0.131, 95% CI: -0.215 to -0.047), 24h-post allergen challenge (-0.098, 95% CI: -0.166 to -0.030). Anti-TSLP antibodies induced sputum eosinophils from baseline: 7h-post allergen challenge (-0.131, 95% CI: -0.239 to-0.023). Anti-TSLP antibodies induced FENO from baseline: 24h-post allergen challenge (-35.925 ppb, 95% CI: -65.098 to -6.751). Anti-TSLP and anti-IgE antibodies induced blood eosinophil counts, which were reported separately in trial.
These data demonstrated that anti-TSLP and anti-IgE antibodies improved EAR and LAR, anti-TSLP and anti- IL13 antibodies improved EAR change from baseline and LAR change from baseline. Anti-TSLP biologicals were also attenuated T2 inflammation biomarkers.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
asthma, mild-moderate, monoclonal antibody, early asthmatic response, late asthmatic response, T2 inflammation.
maximum 3 keywords and no abbreviations, separated by commas
 
321